HK2 and hepatocellular carcinoma: HK2 is the first rate-limiting enzyme of the glycolytic pathway and silencing HK2 in hepatocellular carcinoma inhibits glucose flux to pyruvate and lactate, leading to cell death (DeWaal et al., 2018).